Answers are grounded in this paper and cite their sources.
Commentary highlights the role of BDNF polymorphism in Parkinson's outcomes, suggesting potential for biomarkers.
Parkinson's disease (PD) is characterized by marked clinical and biological heterogeneity, and despite decades of intensive research, no single biomarker has yet been established that can reliably predict disease progression or long-term clinical outcomes. 1Hallmarks of PD pathophysiology-including -synuclein aggregation patterns, nigrostriatal dopaminergic degeneration, motor manifestations, and a wide spectrum of non-motor symptoms-represent essential components of the disease process; however, each captures only a fragment of the
No takes yet. Share an insight, caveat, or question.
Sun Ju Chung (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: